Cytek Biosciences, Inc. (CTKB) vs Lexicon Pharmaceuticals, Inc. (LXRX)
A side-by-side comparison of Cytek Biosciences, Inc. and Lexicon Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTKB
Cytek Biosciences, Inc.
$5.56HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
LXRX
Lexicon Pharmaceuticals, Inc.
$1.75HealthcareDelayed quote: Oct 6, 2026, 12:24 PM EDT
Total return — CTKB vs LXRX
growth of $100 · dividends reinvested · last 5yCTKB -67.5% (-20.1%/yr)LXRX -51.0% (-13.3%/yr)LXRX compounded faster over this window
CTKB LXRX
CTKB vs LXRX: by the numbers
- •LXRX is the larger company ($775M vs $719M market cap).
- •Both run net losses; CTKB's is the smaller (-38.98% vs -147.38% net margin).
- •LXRX grew revenue faster over the past five years (42.36% vs 13.37% CAGR).
Metrics side by side
Valuation
| Metric | CTKB | LXRX |
|---|---|---|
| P/S ratio | 3.48 | 18.69 |
| P/B ratio | 2.23 | 4.44 |
Profitability
| Metric | CTKB | LXRX |
|---|---|---|
| Gross margin | 53.23% | 98.85% |
| Operating margin | -21.60% | -98.21% |
| Net margin | -38.98% | -147.38% |
| ROE | -25.03% | -35.02% |
| ROIC | -12.00% | -23.16% |
Growth (annualized)
| Metric | CTKB | LXRX |
|---|---|---|
| Revenue CAGR (5Y) | 13.37% | 42.36% |
| Total return CAGR (5Y) | -23.16% | -18.54% |
Frequently asked
- Which has grown faster, CTKB or LXRX?
- Over the past five years, LXRX grew revenue faster — CTKB at a 13.37% CAGR versus LXRX at 42.36%.
- How have CTKB and LXRX total returns compared?
- Over the past 5 years, CTKB delivered -23.16% and LXRX delivered -18.54% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Cytek Biosciences ROELexicon Pharmaceuticals ROECytek Biosciences operating marginLexicon Pharmaceuticals operating marginCytek Biosciences revenue growthLexicon Pharmaceuticals revenue growthCytek Biosciences free cash flowLexicon Pharmaceuticals free cash flow
Cytek Biosciences & Lexicon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.